SAR444881

DRUG2 trials

Sponsors

Sanofi, M.D. Anderson Cancer Center

Conditions

CancerNeoplasmSolid Tumors

Phase 1

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

TerminatedNCT04717375

SanofiCancer, Neoplasm

Start: 2021-04-11End: 2025-07-02Updated: 2025-08-07

Phase 2

Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

RecruitingNCT06651593

M.D. Anderson Cancer CenterSolid Tumors

Start: 2025-07-02End: 2030-09-01Target: 40Updated: 2026-07-09

Related Papers

Biomarker study of BND-22 in combination with cemiplimab in solid tumors.

Journal of Clinical Oncology2026-05-28

161TiP A phase I/II, open-label study of an anti-ILT2 (LILRB1) antibody, SAR444881, administered alone and in combination with pembrolizumab, with or without chemotherapy, or cetuximab in patients with advanced solid tumors

Immuno-Oncology Technology2023-12-011 citations

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

Journal for ImmunoTherapy of Cancer2022-09-0134 citations

Evaluation of pharmacodynamic and patient enrichment biomarkers for SAR444881, a first-in-class anti-ILT2 monoclonal antibody for cancer immunotherapy.

Journal of Clinical Oncology2022-06-01